Precision Biosciences Stock Investor Sentiment

DTIL Stock  USD 6.50  0.68  9.47%   
About 66% of Precision BioSciences' investor base is looking to short. The analysis of the overall investor sentiment regarding Precision BioSciences suggests that many traders are alarmed. Precision BioSciences' investing sentiment shows overall attitude of investors towards Precision BioSciences.
  

Precision BioSciences Sentiment by Major News Outlets

Investor sentiment, mood or attitude towards Precision BioSciences can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
a day ago at finance.yahoo.com         
Acquisition by John Kelly of 3000 shares of Precision BioSciences at 6.76 subject to Rule 16b-3
Yahoo News
six days ago at businesswire.com         
Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Tri...
businesswire News
six days ago at gurufocus.com         
JANUS HENDERSON GROUP PLCs Strategic Acquisition in Precision BioSciences Inc
Gurufocus Stories at Macroaxis
over a week ago at gurufocus.com         
Highbridge Capital Managements Strategic Acquisition of Precision BioSciences Shares
Gurufocus Stories at Macroaxis
over two weeks ago at thelincolnianonline.com         
What is HC Wainwrights Estimate for DTIL FY2024 Earnings?
news
over two weeks ago at thelincolnianonline.com         
Precision BioSciences, Inc. CEO Sells 24,668.28 in Stock
news
over two weeks ago at seekingalpha.com         
Precision BioSciences GAAP EPS of -2.25, revenue of 0.6M
seekingalpha News
over two weeks ago at zacks.com         
Disposition of 3012 shares by Michael Amoroso of Precision BioSciences at 8.19 subject to Rule 16b-3
zacks News
over two weeks ago at finance.yahoo.com         
Precision BioSciences Q3 Earnings Snapshot
Yahoo News
over two weeks ago at www.macroaxis.com         
Disposition of 9443 shares by Michael Amoroso of Precision BioSciences subject to Rule 16b-3
Macroaxis News
over three weeks ago at businesswire.com         
Precision BioSciences to Report Third Quarter Results on November 4, 2024
businesswire News
over three weeks ago at businesswire.com         
Precision BioSciences to Host Virtual Investor Event Highlighting PBGENE-HBV Preclinical Safety Data...
businesswire News
over three weeks ago at bizjournals.com         
Biotech pursuing hepatitis B cure reaches milestone
bizjournals News
over three weeks ago at businesswire.com         
Precision BioSciences Presents Preclinical Data Highlighting the Capability of ARCUS for High-Effici...
businesswire News
over three weeks ago at businesswire.com         
Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV F...
businesswire News
Far too much social signal, news, headlines, and media speculation about Precision BioSciences that are available to investors today. That information is available publicly through Precision media outlets and privately through word of mouth or via Precision internal channels. However, regardless of the origin, that massive amount of Precision data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Precision BioSciences news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Precision BioSciences relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Precision BioSciences' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Precision BioSciences alpha.

Precision BioSciences Performance against Dow Jones

 Price Growth (%)  
       Timeline  
1
Disposition of 154 shares by Smith J. Jefferson of Precision BioSciences at 10.32 subject to Rule 16b-3
09/18/2024
2
Precision BioSciences Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635
09/20/2024
3
Wall Street SWOT Precision BioSciences stock navigates gene editing frontier - Investing.com
09/27/2024
4
Cartesian Therapeutics, Inc. Moves 26.9 percent Higher Will This Strength Last
10/04/2024
5
Precision BioSciences to Present at the European Society of Gene Cell Therapy 31st Annual Congress
10/16/2024
6
Precision BioSciences, Inc. Short Interest Down 7.1 percent in September
10/18/2024
7
Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B
10/24/2024
8
Precision BioSciences to Report Third Quarter Results on November 4, 2024
10/29/2024
9
Disposition of 9443 shares by Michael Amoroso of Precision BioSciences subject to Rule 16b-3
11/01/2024
10
Precision BioSciences Q3 Earnings Snapshot
11/04/2024
11
What is HC Wainwrights Estimate for DTIL FY2024 Earnings
11/07/2024
12
Precision BioSciences Highlights Preclinical Data and Outlines Design of First-in-Human Clinical Trial for PBGENE-HBV for Treatment of Chronic Hepatitis B
11/15/2024
When determining whether Precision BioSciences is a strong investment it is important to analyze Precision BioSciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Precision BioSciences' future performance. For an informed investment choice regarding Precision Stock, refer to the following important reports:
Check out Precision BioSciences Hype Analysis, Precision BioSciences Correlation and Precision BioSciences Performance.
For more information on how to buy Precision Stock please use our How to buy in Precision Stock guide.
You can also try the Insider Screener module to find insiders across different sectors to evaluate their impact on performance.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Precision BioSciences. If investors know Precision will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Precision BioSciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
0.4
Revenue Per Share
12.872
Quarterly Revenue Growth
(0.96)
Return On Assets
(0.06)
Return On Equity
0.2444
The market value of Precision BioSciences is measured differently than its book value, which is the value of Precision that is recorded on the company's balance sheet. Investors also form their own opinion of Precision BioSciences' value that differs from its market value or its book value, called intrinsic value, which is Precision BioSciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Precision BioSciences' market value can be influenced by many factors that don't directly affect Precision BioSciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Precision BioSciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Precision BioSciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Precision BioSciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.